Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP14 | P31944 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | CASP4 | P49662 | 1/20 | 0.45 |
| ▸ | CASP5 | P51878 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | CASP9 | P55211 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.45 |
| ▸ | CASP12 | Q6UXS9 | 1/20 | 0.45 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 6/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13057013 | 0.85 | CASP1 (0.62) | EGFRPDGFRBKDRPDGFRACASP1 | |
| SCHEMBL4074929 | 0.78 | CASP1 (0.73) | EGFRPDGFRBKDRPDGFRACASP1 | |
| SCHEMBL3765305 | 0.78 | KDR (0.48) | EGFRPDGFRBKDRCASP1CASP14 | |
| SCHEMBL3753977 | 0.77 | EGFR (0.48) | EGFRPDGFRBKDRPDGFRACASP1 | |
| SCHEMBL3121039 | 0.76 | EGFR (0.74) | EGFRPDGFRBKDRPDGFRAHDAC1 | |
| Hydrochloric Acid SCHEMBL3123796 | 0.75 | EGFR (0.73) | EGFRPDGFRBKDRPDGFRAHDAC1 | |
| SCHEMBL2259237 | 0.73 | CSF1R (0.64) | EGFRPDGFRBKDRPDGFRACSF1R | |
| SCHEMBL2259608 | 0.72 | EGFR (0.74) | EGFRPDGFRBKDRPDGFRAHDAC1 | |
| SCHEMBL3755770 | 0.72 | CASP1 (0.47) | EGFRPDGFRBKDRPDGFRACASP1 | |
| SCHEMBL3758613 | 0.72 | CASP1 (0.47) | EGFRPDGFRBKDRPDGFRACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833803-A4 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | claimed |
| EP-1833803-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | claimed |
| WO-2006074223-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-7842805-B2 | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842805-B2 | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842805-B2 | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| EP-1833803-A4 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1833803-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006074223-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP3, CASP2, CASP5 | EGFR 3245/4885PDGFRB 1533/4885KDR 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.